# FDA recall D-0855-2022

> **Amgen, Inc.** · Class II · drug recall initiated 2022-05-02.

## Product

MVASI (bevacizumab-awwb), Injection, For Intravenous Infusion After Dilution, 100 mg/4 ml, Single dose vial, Rx only, Manufactured by Amgen Inc. Thousand Oaks, CA 91320-1799, NDC 55513-0206-01

## Reason for recall

Defective container: loose crimp defect, potential loss of container integrity.

## Distribution

Nationwide in the USA, Egypt and Lithuania.

## Key facts

- **Recall number:** D-0855-2022
- **Recalling firm:** Amgen, Inc.
- **Classification:** Class II
- **Product type:** drug
- **Status:** Terminated
- **Initiation date:** 2022-05-02
- **Report date:** 2022-05-18
- **Termination date:** 2022-12-02

- **Voluntary/Mandated:** Voluntary: Firm initiated
- **Location:** Thousand Oaks, CA, United States

## Primary source

FDA Enforcement Reports: https://www.accessdata.fda.gov/scripts/ires/index.cfm?Product=D-0855-2022

## Citation

> AI Analytics. FDA recall D-0855-2022. Retrieved 2026-07-19 from https://api.ai-analytics.org/recall/D-0855-2022. Source: US FDA. Licensed CC0.

---

*[Dataset catalog](/datasets/) · [FDA recalls dataset](/datasets/fda-recalls) · CC0 1.0*